Share This Page
Drug Price Trends for NDC 50881-0027
✉ Email this page to a colleague
Average Pharmacy Cost for 50881-0027
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50881-0027
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 50881-0027
Introduction
Understanding the market landscape and future pricing trends for the drug with National Drug Code (NDC) 50881-0027 is essential for stakeholders across pharmaceutical, healthcare, and investment sectors. This comprehensive analysis examines the product’s therapeutic profile, current market position, competitive environment, regulatory factors, and potential pricing trajectories over the coming years.
Product Overview and Therapeutic Profile
NDC 50881-0027 corresponds to Nivestym, a biosimilar version of Neulasta (pegfilgrastim), primarily used for the reduction of infection risk associated with febrile neutropenia in cancer patients undergoing chemotherapy. Biosimilars like Nivestym typically target cost reduction while maintaining comparable efficacy and safety profiles to branded biologics. The biologic nature, combined with regulatory pathways favoring biosimilar entry, influences market dynamics significantly.
Market Landscape and Demand Drivers
The global oncology biosimilar market has experienced robust growth, driven by rising cancer prevalence, patent expirations of established biologics, and healthcare cost containment pressures. The demand for pegfilgrastim biosimilars, including Nivestym, is amplified by growing adoption due to comparable clinical outcomes, improved pricing propositions, and government incentives aimed at expanding biosimilar utilization.
In 2021, the global biosimilars market was valued at approximately $20 billion, with oncology biosimilars representing a significant share [1]. The market share of biologic treatments like Neulasta started declining following patent expiration, creating opportunities for biosimilar entrants such as Nivestym.
Regulatory Status and Price Influencers
Nivestym is approved by FDA, with subsequent market entry in the U.S. in 2018. The biosimilar approval pathway incentivizes lower prices, typically 15-35% below the reference product, depending on indications and payer negotiations. Regulatory frameworks worldwide, notably in Europe and emerging markets, favor biosimilar uptake. Payer policies, hospital procurement strategies, and physician prescribing patterns dramatically influence actual market penetration and pricing.
Current Pricing Environment
In the U.S., the average sales price (ASP) for Neulasta has historically hovered around $7,000-$8,000 per dose, with biosimilars entering the market at approximately 30-40% discounts initially. Nivestym’s list price is generally around 20-35% less than branded Neulasta, aligning with industry norms for biosimilar pricing. Insurance reimbursements and discounting further modify actual transaction prices, with hospitals and payers leveraging formulary negotiations to optimize costs.
Competitive Landscape
Nivestym faces competition from multiple biosimilars, including Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), and other pegfilgrastim biosimilars like Fulphila (bilogisimmpegfilgrastim-jmqp) and Udenyca (pegfilgrastim-cbqv). Market share distribution depends on regional approvals, formulary placement, and physician acceptance.
Most competitors emphasize similar pricing strategies, with discounts ranging from 20-40% from reference biologics initially, gradually stabilizing as market saturation increases. Market incumbents’ negotiation strategies and switching rates heavily influence pricing sustainability.
Future Price Projections (2023-2028)
Short-term outlook (2023-2024):
Upward of early adoption, biosimilar prices are expected to stabilize at approximately 25-30% below the reference Neulasta price, averaging between $5,600 and $6,000 per dose in the U.S. Payers and hospitals’ increasing familiarity with biosimilars will contribute to more aggressive discounts, but supply chain adjustments and manufacturing costs will apply downward pressure.
Medium-term outlook (2025-2027):
Price erosion is anticipated to plateau as biosimilar market penetration matures. Discount rates may reduce to around 20%, aligning with stabilized market shares. Price compression could be mitigated by inflation, supply constraints, and potential regulatory or patent litigations that either prolong or suppress price reductions.
Long-term outlook (2028 onward):
Prices are projected to decline gradually, reaching approximately $4,500–$5,000 per dose, especially as generic biosimilar competition intensifies and biosimilar prescribing becomes the standard of care. The push for pooled procurement and value-based healthcare models could further influence downward pricing pressures.
Influencing Factors and Risks
- Regulatory developments: Streamlined approval pathways and potential exclusivity lifespans may alter market dynamics.
- Healthcare policy: Medicaid, Medicare, and private insurers' formulary decisions significantly impact pricing and adoption.
- Market acceptance: Physician and patient acceptance levels determine actual utilization rates, influencing volume-based pricing.
- Manufacturing costs: Scaling up production may reduce costs, enabling lower prices, but supply chain stability is essential.
- Legal challenges: Patent disputes or litigation delays could influence market entry timing and pricing stability.
Conclusion
NDC 50881-0027’s biosimilar market position is poised for steady growth, with prices expected to remain below the reference brand through 2028. Competitive pressures, evolving regulatory landscapes, and healthcare policies will shape future price trajectories. Stakeholders should monitor these dynamics closely, leveraging strategic negotiations and early adopter insights to optimize economic outcomes.
Key Takeaways
- Nivestym (NDC 50881-0027) benefits from a growing biosimilar market driven by cost-savings imperative in oncology care.
- Initial biosimilar prices are roughly 25-35% below the reference biologic, with stabilization expected around 20-30% discounts in the medium term.
- Market growth hinges on regulatory acceptance, physician adoption, and healthcare policy alignment, impacting long-term pricing.
- Competitive landscape includes multiple biosimilars, necessitating strategic positioning for market share and pricing optimization.
- Future price erosion will be moderated by supply chain, manufacturing efficiency, and policy developments, with prices potentially stabilizing around $4,500–$5,000 per dose by 2028.
FAQs
1. How does the pricing of Nivestym compare to the original Neulasta?
Nivestym is priced approximately 25-35% lower than Neulasta, with actual discounts varying based on negotiations, formulary placements, and market conditions.
2. What factors most influence the price of biosimilars like Nivestym?
Regulatory approval pathways, payer negotiations, competitive biosimilar entries, manufacturing costs, and healthcare policies primarily affect biosimilar prices.
3. Will Nivestym replace Neulasta entirely in clinical practice?
While biosimilars like Nivestym are increasingly adopted, complete replacement depends on physician acceptance, formulary decisions, and patient preferences.
4. How does market competition impact future pricing for Nivestym?
Intense competition among biosimilars will likely drive prices downward, especially as more alternatives become available and market share stabilizes.
5. What is the potential impact of upcoming regulations on biosimilar pricing?
Regulatory frameworks that streamline approval or extend exclusivity periods can influence biosimilar market entry and, consequently, pricing strategies.
References
- Grand View Research. "Biosimilars Market Size, Share & Trends Analysis Report." 2022.
More… ↓
